The WHO is testing three drugs in its search for potential COVID-19 treatments

A malaria drug, a cancer drug and a drug used for people with diseases of the immune system are being tested for use in COVID-19 patients, the WHO says.

The World Health Organization's director-general, Tedros Adhanom Ghebreyesus, says there is a critical need to find more COVID-19 treatments.

The World Health Organization's director-general, Tedros Adhanom Ghebreyesus, says there is a critical need to find more COVID-19 treatments. Source: AAP

The World Health Organization says a clinical trial in 52 countries will study three anti-inflammatory drugs as potential treatments for COVID-19 patients.

"These therapies - artesunate, imatinib and infliximab - were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised COVID-19 patients," it said in a statement on the Solidarity PLUS trial.

The trial involves thousands of researchers at more than 600 hospitals, WHO director general Tedros Adhanom Ghebreyesus told a news briefing from Geneva.
Finland is one of the first countries to enrol patients in the Solidarity PLUS trial, he added.

"Finding more effective and accessible therapeutics for COVID-19 patients remains a critical need," Dr Tedros said.

"There are many variants and all variants can appear anywhere on the planet. And so having so many sites in so many different countries and regions will help us get to these answers as fast as possible," said Marie Pierre Preziosi, co-lead of the research and development blueprint at the WHO.

Artesunate is already used for severe malaria, imatinib for certain cancers and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.
The WHO warned countries to come together to combat the fast-spreading Delta variant of the coronavirus and urged equitable access to essential countermeasures.

"At the current trajectory, we could pass 300 million reported cases early next year. But we can change that. We're all in this together but the world is not acting like it," Dr Tedros said.

The WHO last week called for a halt on COVID-19 vaccine boosters until at least the end of September as the gap between vaccinations in wealthy and poor countries widens.

The original Solidarity trial last year concluded that all four treatments evaluated - remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon - had little or no effect in helping COVID-19 patients.

The WHO expects final results from this trial next month.
So far, only corticosteroids have been proven effective against severe and critical COVID-19.

The WHO said artesunate, produced by Ipca, is used to treat malaria.

In the trial, it will be administered intravenously for seven days, using the standard dose recommended for the treatment of severe malaria.

Imatinib, produced by Novartis, is used to treat certain cancers. In the trial, it will be administered orally, once daily, for 14 days.

Infliximab, produced by Johnson and Johnson, is used to treat diseases of the immune system. In the trial, it will be administered intravenously as a single dose.


Share
3 min read

Published

Updated

Source: AAP, SBS


Share this with family and friends


Get SBS News daily and direct to your Inbox

Sign up now for the latest news from Australia and around the world direct to your inbox.

By subscribing, you agree to SBS’s terms of service and privacy policy including receiving email updates from SBS.

Download our apps
SBS News
SBS Audio
SBS On Demand

Listen to our podcasts
An overview of the day's top stories from SBS News
Interviews and feature reports from SBS News
Your daily ten minute finance and business news wrap with SBS Finance Editor Ricardo Gonçalves.
A daily five minute news wrap for English learners and people with disability
Get the latest with our News podcasts on your favourite podcast apps.

Watch on SBS
SBS World News

SBS World News

Take a global view with Australia's most comprehensive world news service
Watch the latest news videos from Australia and across the world